



APPENDIX B

(Clean Copy of Claims 37CFR 1.121(c)(1))

- 09745776-032001
1. (AMENDED) Prodrug compounds of inhibitors of the enzymatic activity of dipeptidyl peptidase IV (DP IV), which compounds have the general formula A-B-C, wherein
A is an amino acid,
B is a chemical bond between A and C or is an amino acid, and
C is a stable inhibitor of DP IV without C-terminal phosphonate residue.
 2. (AMENDED) The compounds according to claim 1, wherein B is selected from a group consisting of proline, hydroxyproline, thiazolidinecarboxylic acid, dehydroproline, pipecolic acid, azetidinecarboxylic acid or aziridinecarboxylic acid.
 3. (AMENDED) The compounds according to claim 1 wherein B is selected from a group consisting of proline or hydroxyproline.
 4. (AMENDED) The compounds according to claim 1 wherein said stable inhibitor is selected from a group consisting of aminoacylpyrrolidide, aminoacylthiazolidide or N-dipeptidyl, O-acyl hydroxylamine.
 5. (AMENDED) The compounds according to claim 1 wherein said stable inhibitors are present in salt form.
 6. (AMENDED) The compounds according to claim 1 wherein A-B is a dipeptide of formula Ile-Pro or Gly-Pro.
 7. (AMENDED) A pharmaceutical composition for oral administration containing prodrug compounds of inhibitors of dipeptidyl peptidase IV wherein said composition comprises at least one prodrug compound optionally in combination with customary carriers or excipients.

a

8. (AMENDED) A method of using compounds of stable inhibitors of dipeptidyl peptidase IV in a pharmaceutical compositions in the preparation of a pharmaceutical composition for the temporally controlled in vivo inhibition of DP IV comprising providing a compound of the general formula A-B-C, wherein

A is an amino acid,

B is a chemical bond between A and C or is an amino acid, and

C is a stable inhibitor of DP IV without C-terminal phosphonate residue.

9. (AMENDED) The method of claim 8 wherein said use is in cell, tissue or organspecific enzymatic inhibition of DP IV.

10. (AMENDED) A method of treating metabolic disorders in mammals that can be treated by modulating the DP IV enzymatic activity of a mammal comprising of the step of administering to said mammal a compound of the general formula.

11. (AMENDED) The method of claim 10 wherein said treatment is in the treatment of metabolic disorders in humans.

12. (AMENDED) The method of claim 10 wherein, said compounds are used to treat impaired glucose tolerance, glucosuria, hyperlipidaemia, metabolic acidoses, diabetes mellitus, diabetic neuropathy, obesity and nephropathy and of sequelae of diabetes mellitus in mammals.

13. (NEWLY ADDED) The compounds of claim 1 wherein said compounds comprise said stable inhibitor of DP IV within a complex comprising said prodrug, said prodrug preventing the degradation and increasing the activity of said stable inhibitors.